Stop in the Name of Fraud?: After-the-Fact Fraud Allegation Does Not Divest ASBCA of Jurisdiction
Client Alert | 1 min read | 08.21.20
In Mountain Movers/Ainsworth-Benning, LLC, the Armed Services Board of Contract Appeals addressed whether the Board retains jurisdiction over an appeal of a contractor’s claim when a contracting officer (CO) rescinds a final decision based upon a contractor’s alleged fraud. During the appeal, the CO rescinded the final decision, asserting that the contractor had previously made misrepresentations related to the contract. The CO issued a new final decision stating that the contractor’s alleged misrepresentation divested the CO of authority to decide the claim, and cited to FAR 33.210(b), which states that COs do not have the authority to settle, compromise, pay, or adjust any claim involving fraud. The Government then moved to dismiss the appeal for lack of jurisdiction, arguing that there was no longer an appealable final decision. The Board rejected the Government’s argument, and held that it possessed jurisdiction over the prior final decision, which had decided the claim on the merits and was appealed before the CO’s rescission. The Board also noted that the Contract Disputes Act may divest a CO of authority to resolve claims when the alleged fraud relates to the claim, but not when there is just a belief of possible fraud during contract performance. This decision is consistent with recent Board case law finding jurisdiction over appeals when there is an allegation that the contractor committed fraud during contract performance, and makes clear that the Government cannot divest the Board of jurisdiction simply by making allegations of performance fraud either post hoc or unrelated to the “claim.”
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection



